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Background: Synthetic antisense molecules have an enormous potential for therapeutic applications in humans.
The major aim of such strategies is to specifically interfere with gene function, thus modulating cellular pathways
according to the therapeutic demands. Among the molecules which can block mRNA function in a sequence
specific manner are peptide nucleic acids (PNA). They are highly stable and efficiently and selectively interact with
RNA. However, some properties of non-modified aminoethyl glycine PNAs (aegPNA) hamper their in vivo
applications.
Results: We generated new backbone modifications of PNAs, which exhibit more hydrophilic properties. When we
examined the activity and specificity of these novel phosphonic ester PNAs (pePNA) molecules in medaka (Oryzias
latipes) embryos, high solubility and selective binding to mRNA was observed. In particular, mixing of the novel
components with aegPNA components resulted in mixed PNAs with superior properties. Injection of mixed PNAs
directed against the medaka six3 gene, which is important for eye and brain development, resulted in specific six3
phenotypes.
Conclusions: PNAs are well established as powerful antisense molecules. Modification of the backbone with
phosphonic ester side chains further improves their properties and allows the efficient knock down of a single gene
in fish embryos.
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Antisense oligonucleotides are designed for sequence
specific binding of complementary regions on their tar-
get mRNA. The binding either results in mRNA cleav-
age, caused by the activation of endonucleases RNase H
or L [1], or in the inhibition of translation [2]. Different
modifications of the nucleic bases or the backbone were
introduced to improve their activity and biological stabil-
ity. In morpholino antisense molecules, the ribose is
replaced by morpholino rings and non-ionic phosphoro-
diamidate is used instead of phosphodiester linkages [3].
Their binding strength closely resembles that of RNA or* Correspondence: thomas.czerny@fh-campuswien.ac.at
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reproduction in any medium, provided the orDNA molecules, therefore, molecules with a length of
25 nucleotides are used for efficient transcriptional
blockage. For translational blocking the 5’ untranslated
region or the region around the start codon of the target
mRNA are selected [4]. Morpholino oligomers can also
be used for efficient blocking of the splice machinery [5].
The highly specific effect of morpholino oligomers on
gene silencing could be demonstrated in sea urchins [6],
Xenopus [7], Zebrafish [8] and Medaka [9]. Today mor-
pholino oligos represent the gold standard for gene spe-
cific knock down in many species.
In 1991 Nielsen and colleagues created peptide nucleic
acids (PNA) which instead of the phosphate ribose ring of
DNA contain a polyamide backbone of N-(2-aminoethyl)-
glycine (aeg) units [10]. aegPNAs bind to complementary
RNA or DNA in a sequence-specific manner [11,12]. The
chemical structure is responsible for a high stability against
proteases, nucleases as well as thermal and pH fluctuations
[13]. The entire neutral charge of the molecule decreasesd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Figure 1 Chemical structure of PNAs. Schematic structure of
aegPNAs, pePNAs, mixed PNAs (containing both aeg- and pePNA
monomers) and HypNA-pPNAs is shown. pePNAs contain
C2-phosphonoester residues, mixed PNAs contain C3-residues.
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hybridization affinity with RNA and DNA. Consequently
short probe lengths (13–18 bases) are sufficient for select-
ive binding, thereby reducing the probability for forming
secondary structures [13-15]. In addition, the introduction
of mismatches has a stronger effect on the stability of
PNA/DNA interactions in comparison to DNA/DNA
duplexes, demonstrating the high specificity of PNAs [16].
Several in vitro techniques make use of the extraordinary
affinity of PNAs [17,18]. In vivo techniques also strongly
benefit from the highly specific binding to mRNAs,
however, so far unmodified aegPNAs have not been suc-
cessful in injection experiments for gene specific knock
down in animal models [19]. One problem for the appli-
cation of PNAs is the low solubility due to the absence
of charges. Introduction of negative charges by forming
hetero-oligomers of alternating trans-4-hydroxy-L-proline/
phosphonate polyamides with DNA bases (HypNA-pPNA)
allowed specific down regulation of target genes in zebra-
fish embryos [20]. In addition, various end-modifications
of PNAs have been developed, which mainly address the
improvement of their cell delivery [21,22].
Here we tested the modification of the PNA backbone
in order to keep the conformation most similar to the
well established original aegPNAs. The resulting pePNAs
contain phosphonic ester side chains in an otherwise
non-modified polyamide backbone. The neutral pePNAs
are highly soluble, but keep the high affinity and specifi-
city of aegPNAs. In particular mixed versions of pe- and
aegPNA components show favourable properties. We
demonstrate the efficiency of these new antisense mole-
cules by blocking gfp expression and in vivo down regu-
lation of six3 gene function in medaka embryos.
Results and discussion
Synthesis of novel peptide nucleic acids
aegPNAs bind corresponding RNA sequences with high
affinity and specificity, however, unfavourable properties
like their low solubility hamper their application in vivo.
By employing the building blocks shown in Additional
file 1: Figure S1, we introduced phosphonic ester side
chains into the otherwise non-modified backbone of
aegPNAs. As a result novel phosphonic ester PNA variants
(pePNA) were obtained (see Figure 1).
First we investigated the properties of a 15mer pePNA.
The oligomer exhibited good solubility in water and we
were able to prepare highly concentrated stock solutions
(10 mM). However, it turned out that pePNAs capped
with acetyl at the C-terminus tend to form stable foam
after sonification at this concentration. A possible ex-
planation might be the large number of phosphonic
esters residues, which introduce a highly polar but not
ionic character into the oligomer. The tendency to form
foams was not observed when the pePNAs werepermanently charged with trimethyl-lysine (TML) at the
C-terminus prior to capping with acetyl (see Additional
file 1: Figure S1).pePNAs efficiently block translation of gfp mRNA
In order to establish conditions for the application of
pePNA molecules for antisense approaches we estab-
lished an assay for translation blocking. Cell culture
based assays include the problem of the transport of
PNAs (or PNA/DNA duplexes) into the cells [23]. To
use an unbiased strategy we therefore used injection into
fish embryos. The pePNAs were co-injected together
with gfp mRNA into medaka embryos at the one-cell
stage. As target sequence within the gfp mRNA we
selected a region directly after the AUG (see Figure 2),
which previously had been used for knock down strategies
with morpholino oligos [9]. The embryos continued devel-
opment and 24 hours later the gfp signal was observed
under the fluorescence microscope. According to the gfp
expression level, the embryos were categorized into 4
groups with strong, moderate, weak and no gfp signal, re-
spectively (Figure 3A-D). To consider the small variations
of the injection procedure, we calculated an overall num-
ber of gfp signal intensity for all embryos, which is based
on different weights for the individual groups of embryos.
For this calculation, strong embryos were weighted with
100%, embryos of the moderate group with 30%, those of
the weak group with 10% and those showing no gfp signal
were counted with 0%. From this an average number for
all embryos was derived and then corrected by those for
the injection of mRNA alone. The resulting value repre-
sents the average gfp intensity in % (mRNA alone results
in 100%).
Figure 2 Sequences of the antisense molecules and their targets. The mRNA targets are shown in the 5’-3’ orientation, capital letters
indicate the coding region. The AUG start codon is marked by red overlay. A morpholino oligo is indicated by MO (Six3-MO). All other sequences
represent PNAs, pePNA-C2 components are shown in black, pePNA-C3 components in red and aegPNAs components are marked by gray
overlay. Underlined bases (black) represent mismatches. All PNA and morpholino oligos are shown in the 3’-5’ (NH2-H for PNAs) orientation. L means
trimethyl-lysine and LLLL a combination of 4 such residues. SuRho indicates sulforhodamine B.
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the oligomers (12mer, 14mer, 16mer and 17mer; for se-
quence information see Figure 2). The pePNAs (200 μM)
were co-injected with 10 ng/μl gfp mRNA. Although all
PNA lengths were able to reduce the gfp signal in the
embryos (Figure 3E and Additional file 2: Table S1), the
strongest effect was observed for the 16mer PNA (Gfp16;
reduction to 28% average gfp intensity).
To investigate the influence of the steric hindrance of
the phosphonic ester residues, we synthesized a second
set of 15 and 16mers. In this set an additional methylene
group was introduced into the side chain (R-C3 instead
of R-C2; see Figure 1) to elongate the alkyl spacer be-
tween the phosphonic esters and the oligomer backbone.
Furthermore, the number of side chains was reduced,
forming a hybrid oligomer of pe- and aegPNA compo-
nents. We hypothesised an increased binding efficiency
of these mixed PNAs and indeed found a high melting
point (66.9°C) for Gfp16mix with complementary DNA.
On the contrary a corresponding pure pePNA (Gfp17)
showed a considerably lower melting point of 57.8°C
(although containing one additional nucleotide com-
pared to Gfp16mix). The presence of the aegPNA
monomers in the molecules thus increased the binding
affinity and this consequently resulted in a stronger re-
duction of the gfp signal compared to C2-pePNAs
(data not shown). We therefore increased the amount
of gfp mRNA for the co-injection assay to 20 ng/μl.This resulted in stronger gfp intensity, which allowed
us to better evaluate the improved antisense effect of
the mixed PNAs. At a concentration of 200 μM, a
15mer PNA with a mixed backbone (Gfp15mix)
showed a reduction to 59% of the gfp fluorescence in-
tensity. This result could be improved when a 16mer
mixed PNA (Gfp16mix) was injected (41%), demon-
strating a superior effect of 16mer PNAs also for mixed
backbones. Similar effects were observed for a mixed
PNA containing 4 TML residues (Gfp16mixL4). At
higher concentrations of 400 μM or 600 μM the average
gfp intensity was reduced to minimum levels of 12%. As a
control for the specificity of the PNAs, we used a refer-
ence PNA with a completely unrelated sequence
(Ref15mix). The gfp level in this control experiment was
similar to the group of injected embryos without adding
PNAs (Figure 3F). Furthermore, we did not observe any
toxicity of the PNAs in the fish embryos at higher concen-
trations (up to 600 μM; see death rates in Additional file
3: Table S2).
Uniform distribution of PNA molecules in medaka
embryos
To get more information about the fate of the PNAs
in the embryos, we injected a sulforhodamine labeled
mixed PNA variant (Gfp16mixRho; for sequence infor-
mation see Figure 2). After injection at the one-cell stage
the PNA distributed equally into the dividing blastomeres
Figure 3 Translational blocking of pePNAs after injection of gfp mRNA into medaka embryos. The pePNAs were coinjected with gfp
mRNA into medaka embryos at the one cell stage. 24 hours later the intensity of the gfp fluorescence was qualified as weak (B), moderate (C;
mod) or strong (D). (A) Shows an uninjected embryo (no signal, corresponding to a complete knock down of gfp). The embryos are shown in a
dorsal view, anterior to the top. A graph summarizing the experiments for optimisation of the PNA length is shown in (E). The names of the
PNAs are explained in Figure 2. The embryos were injected with a mixture of 10 ng/μl gfp mRNA and 200 μM PNAs preincubated for 30 minutes
on ice. After 24 hours the embryos were divided into groups according to their gfp signal intensity. Above the columns the calculated average
gfp intensity in percent is indicated (see text for calculation). Similarly the results for mixed PNAs are shown in (F). Injections and evaluations
were performed as in (E), except that 20 ng/μl mRNA were used. Note that the increased amount of mRNA results in higher numbers of average
gfp intensity for comparable antisense function.
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PNA in the embryo could also be observed at later stages,
no signals were detected in the yolk. Using this labeled
PNA we were able to exactly quantify the injection volume
and the final concentration of the PNAs in the embryo. As
a reference we used small beads (average 730 μm), which
were soaked for several days with a defined concentration
of the PNA. A comparison of the fluorescence signals of
these beads with the injected embryos allowed us to deter-
mine the injection volume to 11.3 nl on average. Injection
of antisense molecules at 100 μM consequently resulted in
a concentration of 25 μM in the embryonic cells (the
volume of the embryo was determined at the four-cell
stage at 33 nl, for calculations see Methods section).
Here uniform distribution within the cells was assumed.
Knock down of the six3 gene in medaka embryos by
mixed PNAs
The Gfp-PNA molecules were tested in an in vivo set-
ting, but the mixing of gfp-antisense PNAs with the gfp
mRNA in the injection solution could lead to PNA/RNAhybridization prior to injection into the embryos. To
avoid this possibility, we decided to test the targeting
specificity of the PNAs in a complex in vivo environ-
ment, with a large excess of non-target mRNA. We
therefore selected the endogenous six3 gene as a target
for PNA knock down experiments.
Six3 is part of the Six family of proteins, whose mem-
bers are characterized by the presence of an N-terminal
Six domain and a homeodomain [24]. Six genes are
highly conserved across the animal kingdom. In Dros-
ophila the six3 homologue optix fulfills important func-
tions in the development of the visual system [25]. In
vertebrates, six3 and six6 are expressed in developing
areas of the lens, neural retina, retinal-pigmented epithe-
lium, nasal placodes, optic chiasm and forebrain. They
take over important tasks in forming the rostral brain
and the eye, especially the retina and the lens [26-28].
The critical function in eye development could also be
demonstrated in medaka where inactivation of six3 by
morpholino knock-down resulted in lack of forebrain
and eye structures [9].
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sized a 16mer mixed C3-PNA for the knock down
experiments (referred to as Six3mix; for sequence infor-
mation see Figure 2). The chosen sequence is a subset of
a published morpholino 25mer directed against the six3
5’-region, directly upstream of the start codon [9]. After
injection of the Six3mix-PNA a variety of eye and fore-
brain phenotypes were observed, in good agreement
with previous results obtained for morpholino oligos in
medaka embryos [9]. Based on the eye and forebrain
phenotypes and in agreement with the literature [9] we
divided these embryos into three groups. Embryos with
a weak phenotype showed a size reduction of the eyes,
which at the anterior part pointed towards the midline
(Figure 4A arrows). Embryos with a cyclopic eye pheno-
type or strongly reduced eye size were characterized as
moderate phenotype and embryos with almost no eye
and forebrain formation were determined as strong
phenotype (Figure 4A). The eye and forebrain pheno-
types in Six3mix-PNA injected embryos were then con-
firmed by analyzing the expression of the winged-helix
transcription factor bf1. It has been shown that bf1 is es-
sential for forebrain and eye development [29-31] and is
regulated by Six3 [32]. As expected the bf1 expression
was strongly reduced in Six3mix-PNA injected embryos,
especially in those with strong eye and forebrain pheno-
types (Figure 4B).
The frequency of the obtained phenotypes was
dependent on the Six3mix-PNA concentration. Whereas
at lower concentrations (e.g. 50 μM) only 10% of the
surviving embryos showed a weak phenotype, at higher
concentrations (e.g. 400 μM) up to 95% of the surviving
embryos exhibited eye and forebrain phenotypes
(Figure 4A,C). A further increase of the PNA concentra-
tion to 900 μM only slightly improved the proportion of
strong phenotypes, however, the frequency of mortality
increased dramatically (82%; 51 of 62 injected embryos)
indicating toxic effects of mixed PNAs at higher
concentrations.
A critical question was how the introduced side chain
modifications of the pePNA components affected the
in vivo knock down efficiency compared to unmodified
aegPNAs. Contrary to negative results reported for un-
modified aegPNAs in fish embryos [19], we observed
gene specific phenotypes in the injected embryos. How-
ever, mixed PNAs were more efficient than aegPNAs
when compared directly (aeg- and mix-PNAs of the
same length and sequence were used, both modified
with TML at the C-teminus; see Figure 2). At 400 μM,
where Six3mix-PNAs showed six3 specific phenotypes in
95% of the surviving embryos, injection of Six3-
aegPNAs resulted in only 54% affected embryos
(Figure 4D and Additional file 5: Table S3). Furthermore,
the fraction of strong phenotypes was largely reducedcompared to Six3mix-PNAs (16% strong phenotypes for
Six3-aegPNA versus 65% for Six3mix-PNA; calculated
from Additional file 5: Table S3; see also Figure 4D). Fi-
nally, also the toxicity of aegPNAs was higher compared
to mixed PNAs (compare death rates in Additional file
5: Table S3). At higher concentrations (600 μM) the
results for the two PNA types was similar, however here
the high death rate (>50%) indicates already considerable
toxicity for both PNAs.
To examine the selectivity and the toxicity of the
modified PNAs, we compared the frequency of the mor-
tality and the obtained eye phenotypes in Six3mix-PNA
injected embryos with two other control groups. First
we injected a mixed PNA of the same length, but with a
completely unrelated sequence (Ref16mix-PNA). Al-
though the frequency of dead embryos slightly increased
up to 400 μM PNA concentration, the surviving
embryos did not show any malformations (Figure 4A;
Ref16mix-PNA 400 μM). As a second control experi-
ment to evaluate the selectivity of the antisense function
we synthesized a 16mer mixed PNA with a single mis-
match (Six3mix-mut-PNA; for sequence information see
Figure 2). Although the mutant PNA also resulted in
six3 specific phenotypes, the frequency of embryos with
eye and forebrain phenotype was strongly reduced
(Figure 4D and Additional file 5: Table S3), suggesting
that a single point mutation strongly affects the target
selection of the mixed PNAs. This property offers the
possibility to design highly specific antisense molecules
that are able to select between individual allelic
sequences, differing by single point mutations.
We next compared the Six3mix-PNAs directly with
morpholino oligos, which represent the standard anti-
sense molecules used for gene specific knock down in
fish embryos [8]. We used a published target sequence
for the medaka six3 gene [9], which overlaps with our
PNA sequences (for sequence information see Figure 2).
We carefully compared the phenotypes at different em-
bryonic stages. Morphologically, Six3mix-PNA injected
embryos were not distinguishable from those injected
with the morpholino oligo (data not shown), but they
already appeared at lower concentrations compared to
the PNAs (between 50 and 100 μM; see Additional file
5: Table S3). The appearance of unspecific phenotypes is
well established for high concentrations of morpholino
oligos [33]. We observed such phenotypes at concentra-
tions of 200 μM, which already result in a high mortality
rate of 90% (see Figure 4E and Additional file 5: Table
S3). Again these unspecific phenotypes were highly simi-
lar to those observed for high doses of PNAs (a typical
embryo is shown in Figure 4A), suggesting similar un-
specific effects of both antisense molecules in the central
nervous system and the eyes. For both morpholino oli-
gos and PNAs the unspecific phenotypes only appeared
Figure 4 Injection of medaka embryos with Six3-PNAs. A wild-type embryo (no PNA injection) at 3 days is shown in (A). Embryos injected
with 400 μM Ref16mix-PNA are indistinguishable from wild-type embryos; at 900 μM unspecific phenotypes were detected (both in A). The
Six3mix-PNA injected embryos were evaluated 3 days after injection at stage 29. The phenotypes were divided into weak, moderate and strong
(for criteria see text). Arrows indicate the anterior parts of the eyes pointing to the midline in weak phenotypes. The black arrowhead indicates
remnants of the eye structures. All embryos in (A) are at stage 29 (34 somites). In (B) the expression of the bf1 gene in wild-type and strongly
affected embryos injected with Six3mix-PNAs is shown (both at stage 22; 9 somites). Note the presence of bf1 expression in the otic vesicles, both
in wild-type as well as in Six3mix-PNA injected embryos (marked by red arrowheads). Dorsal views of the anterior part of the embryos are shown.
The quantitative evaluation of the six3 knock down experiments is shown in (C) and (D) for the indicated PNA molecules. The percentages of
phenotypes for the diagrams were calculated from the surviving embryos. PNAs shown in (D) were injected at 400 μM. (E) Shows the mortality
rate of embryos injected at the indicated concentration (survival was examined 24 hrs after injection, see also Additional file 5: Table S3).
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rates (200 μM for morpholino oligos and 600-900 μM
for mix-PNAs). In addition they were clearly distinguish-
able from the six3-specific phenotypes and also appearedin embryos injected with high amounts of the control
PNA Ref16mix, these embryos however lacked any six3
specific phenotypes. To further extend the comparison,
we performed a series of in situ hybridisation experiments.
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mix-PNA injected embryos (see Additional file 6: Figure
S3). Therefore, both types of antisense molecules generate
the same range of six3-specific phenotypes in medaka
embryos and also lead to highly similar unspecific effects
at high doses. Similar to previous observations [3], we saw
a higher efficiency of morpholino oligos at low concen-
trations. Morpholino oligos show a lower affinity for
RNA compared to PNAs of the same length [34]. Our
modification of aegPNAs into mixed PNAs resulted in
enhanced knock down efficiency and interestingly, also
in reduced affinity (see melting point determinations
above). Therefore properties different from the affinity
must account for the high efficiency of morpholino oli-
gos, however, also the toxicity of these molecules peaks
at substantially lower concentrations compared to the
mixed PNAs (see Figure 4E).
To further demonstrate the specificity of the six3
knock down, we injected a completely unrelated 16mer
mix-PNA, directed against a sequence downstream of
the six3 AUG (Six3mix2; see Figure 2). The efficiency of
this PNA was weak, since no phenotypes were observed
at lower concentrations, however at 600 μM the
expected typical six3-phenotypes appeared (see Add-
itional file 5: Table S3). Therefore, two independent
mixed PNAs directed against the six3 mRNA resulted in
the same gene-specific phenotypes, which are indistin-
guishable from those caused by morpholino oligos. Fi-
nally we performed a rescue experiment. For this
purpose we generated mRNA of the human six3 gene,
which does not contain the targeted sequences of the
medaka six3. At higher concentrations (25 and 50 ng/μl),
injection of this mRNA causes specific phenotypes
(enlarged eyes and ectopic retina, data not shown), we
therefore switched to lower concentrations of 5 and
10 ng/μl. In a control experiment co-injection of gfp-
mRNA with 400 μM Six3mix-PNA resulted in the
expected phenotypes (see Additional file 7: Figure S4).
However co-injection of hSix3-mRNA strongly reduced
the overall number of six3-phenotypes (from 52% for the
control embryos to 14 and 11%, respectively). Further-
more, no strong and moderate phenotypes appeared in
these embryos any more. Therefore, the rescue experi-
ments further demonstrate the specificity of the six3
knock down by the mixed PNAs.
Conclusions
PNAs are highly efficient antisense molecules, which
bind their mRNA target sequences with high affinity.
However, some properties make their application in vivo
difficult. Contrary to previous observations [19] we show
here that unmodified aegPNAs can be used for the spe-
cific knock down of genes in living animals. However,
the introduction of phosphonic ester side chains to thebackbone improves the properties of the PNAs consider-
ably. The increased hydrophilicity resulted in high solu-
bility and the modified pePNAs worked efficiently in
translational blocking of mRNA. The combination with
aegPNAs in mixed molecules combined the favourable
hydrophilic properties of the pePNAs with the superior
binding affinity of aegPNAs. As a result, we could dem-
onstrate an efficient and highly specific knock down of a
single medaka gene in vivo.Methods
PNA synthesis
PNA monomer building blocks are commercially avail-
able. Optical pure (R-configuration according to CIP
rules) pePNA monomer building blocks were synthe-
sized according to a route reported previously [35-37].
N2-Boc-N6, N6, N6-trimethyl-(L)-lysine iodide (TML) as
building block was prepared as published by Chen and
Benoiton [38]. A schematic presentation of the building
blocks is shown in Additional file 1: Figure S1. Ethyl
esters of phosphonic acid are highly stable under physio-
logic conditions and against esterases [39]. All PNAs
were synthesized on a fully automated solid phase
synthesizer (Multisynthec Syro) according to a protocol
developed by Koch [40]. aegPNAs (Six3-aegPNA) were
synthesized by Eurogentec.
The PNAs were dissolved in nuclease free water by re-
peatedly shaking and vortex ting. Finally they were gently
sonicated for 2 minutes with repeated pulses. Subse-
quently the PNAs were divided into aliquots of 100 μl
(2 mM final concentration) and kept at −80°C.Measurement of melting points
The melting points of PNA-DNA duplexes were deter-
mined in Dulbecco’s PBS (1x) without Ca & Mg with a
Thermo Genesys 10s UV–vis Spectrometer and a heated
cuvette (Haake F3 S water bath).Microinjection into medaka embryos
Embryos of the medaka Cab strain were used for all
experiments. Stages were determined according to Iwa-
matsu [41]. For the gfp experiments, first mRNA of gfp
was in vitro transcribed using the T7 High Yield Message
Marker Kit (Ambion) according to the manufacturer's
instructions. The injection solution containing gfp
mRNA (10 or 20 ng/μl), PNAs (50-600 μM) and Ribo-
Lock RNase inhibitor (2units/μl; Fermentas) were mixed
on ice and then injected into embryos at the one-cell
stage. Injection of six3 antisense molecules was done at
concentrations of 50–1200 μM PNAs or morpholino oli-
gos. After injection the embryos were incubated at nor-
mal conditions (1x ERM buffer at 27°C).
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Sulforhodamine labeled PNAs (Gfp16mixRho) were
injected at concentrations of 50 μM, 100 μM, 500 μM
and 900 μM at the one-cell stage. At the four-cell stage
pictures were made under the fluorescence microscope
at standardised exposure times (1 ms, 10 ms, 100 ms
and 1000 ms) and quantified using the ImageJ
programme (background values were subtracted from all
samples and only intensities within a linear range were
considered for the quantification). For comparison, cel-
lulose sulphate beads with an average diameter of
730 μm were soaked several days with the labeled PNA,
shortly washed and then treated the same way under the
fluorescence microscope. The volume of the embryo at
the four-cell stage was determined by measuring the
average diameter of the blastomeres (250 μm) resulting
in a volume of 33 nl for the embryo. Using the volumes
of the beads and the embryos the internal concentration
of the PNA in the embryos could be calculated and
resulted in an average value of 25.7 μM for injections
with 100 μM PNA (injections were performed in a re-
producible manner). The average injection volume
therefore was 11.3 nl. All experiments were done in 5
fold repetitions.
Whole-mount in situ hybridization
Whole-mount in situ hybridization using DIG-labeled
probes was performed as described previously [42].
Additional files
Additional file 1: Figure S1. Building blocks used for the chemical
synthesis.
Additional file 2: Table S1. Optimisation of the PNA length. The names
of the PNAs are explained in Figure 2. The embryos were injected with a
mixture of 10 ng/μl gfp mRNA and 200 μM PNAs preincubated for
30 minutes on ice. After 24 hours the embryos were divided into groups
according to their gfp signal intensity. The average gfp intensity of the
surviving embryos was then calculated as described in the text.
Additional file 3: Table S2. Antisense function of mixed PNAs on gfp
mRNA. Injections and evaluations were performed as described in Table
1, except that 20 ng/μl mRNA was used. Note that the increased amount
of mRNA results in higher numbers of average gfp intensity for
comparable antisense function.
Additional file 4: Figure S2. Distribution of mix-PNAs in the embryo.
Medaka embryos injected with 100 μM solution of Gfp16mixRho are shown
in the 2-cell stage (A) and stage 24 (16 somites; B). A dashed line indicates
the outline of the yolk. A lateral view of the embryo is shown in B.
Additional file 5: Table S3. Six3 knock down by PNAs. PNAs and
morpholino oligos were injected at the indicated concentrations and the
embryos evaluated after 3 days at stage 29 according to the severity of
the phenotype. “Phenotypes in surviving” indicates the percentage of
surviving embryos showing six3 phenotypes.
Additional file 6: Figure S3. Comparison of mixed PNA and
morpholino phenotypes. Embryos were injected with 400 μM Six3mix-
PNA (PNA) or 100 μM Six3-MO (MO) and at stage 20 analysed by in situ
hybridisation with probes for pax2 and rx2. Typical results are shown for
each group of weak, moderate and strong phenotypes, wildtype (WT)
embryos are shown as a reference. An arrowhead marks pax2 expressionin the mid-hindbrain boundary, note the reduced expression in the
strong group. The eye vesicles in the weak group are smaller compared
to wildtype embryos, in the moderate group their size is further reduced,
in the strong group no eye vesicles were detectable.
Additional file 7: Figure S4. Rescue of Six3mix-PNA injected embryos.
Embryos were injected with 400 μM Six3mix-PNA (PNA) together with
gfp-mRNA (10 ng/μl) or hSix3-mRNA (5 and 10 ng/μl). The phenotypes
were then determined according to criteria described in the text.
“Phenotypes in surviving” indicates the percentage of surviving embryos
showing six3 phenotypes.
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